Leukemia Research
Volume 33, Issue 9 , Pages 1183-1188 , September 2009

Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes

  • Julie Schanz

      Affiliations

    • Georg-August-University, Department of Haematology and Oncology, Robert-Koch-Str. 40, 37075 Goettingen, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 551398535; fax: +49 551398587.
    • ,
  • Heike Jung

      Affiliations

    • Georg-August-University, Department of Haematology and Oncology, Robert-Koch-Str. 40, 37075 Goettingen, Germany
    • ,
  • Bernhard Wörmann

      Affiliations

    • Klinikum Braunschweig, Medizinische Klinik III, Celler Straße 38, 38114 Braunschweig, Germany
    • ,
  • Winfried Gassmann

      Affiliations

    • Marien-Hospital, Medizinische Klinik III, Kampenstraße 51, 57072 Siegen, Germany
    • ,
  • Thomas Petersen

      Affiliations

    • Klinikum Braunschweig, Medizinische Klinik III, Celler Straße 38, 38114 Braunschweig, Germany
    • ,
  • Axel Hinke

      Affiliations

    • WiSP GmbH, Karl-Benz-Str. 1, 40764 Langenfeld, Germany
    • ,
  • Detlef Haase

      Affiliations

    • Georg-August-University, Department of Haematology and Oncology, Robert-Koch-Str. 40, 37075 Goettingen, Germany

Received 6 May 2008 ,Revised 3 March 2009 ,Accepted 20 March 2009.

References 

  1. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood. 1996;88:4275–4287
  2. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 pts. with myelodysplastic syndromes. Blood. 1995;86:268–276
  3. Yoshida Y, Anzai N, Kawabata H. Apoptosis in myelodysplasia: a paradox or paradigm. Leuk Res. 1995;19(12):887–891
  4. Raza A, Alvi S, Broady-Robinson L, Showel M, Cartlidge J, Mundel SD, et al. Cell cycle kinetic studies in 68 pts. with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine. Exp Hematol. 1997;25:530–535
  5. Kurotaki H, Tsushima Y, Hagai K, Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol. 1999;102:115–123
  6. Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. ‘Low-risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol. 1998;103:1075–1082
  7. Farquhar MJ, Bowen DT. Oxidative stress and the myelodysplastic syndromes. Int J Hematol. 2003;77:342–350
  8. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol. 1999;26:3–21
  9. Acosta JC, Richard C, Delgado MD, Horita M, Rizzo MG, Fernández-Luna JL, et al. Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol Cancer Ther. 2003;2:893–900
  10. Khodarev NN, Kataoka Y, Murley JS, Weichselbaum RR, Grdina DJ. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC). Int J Radiat Oncol Biol Phys. 2004;60:553–563
  11. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol. 1996;23:58–63
  12. Klimecki W, Heaton R, Glinsmann-Gibson B, List AF. Amifostine suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor growth via polyamine-like effects. Blood. 1997;90(Suppl. 1):[abstract 2319]
  13. Romano MF, Lamberti A, Bisogni R, Garbi C, Pagnano AM, Auletta P, et al. Amfostine inhibits hematopoietic progenitor cell apoptosis by activatig NF-κB/Rel transcription factors. Blood. 1999;94:4060–4066
  14. Invernizzi R, Pecci A, Travaglino E, Gobbi PG, Malabarba L, Ramajoli I, et al. Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes. Br J Haematol. 2002;118:246–250
  15. Moroni M, Porta C, Invernizzi R, Inzoli A, Bobbio-Pallavicini F, Bobbio-Pallavicini E. ‘Tunel’ evidence of reduced bone marrow cells apoptosis in a refractory anemia patient treated with amifostine. Br J Haematol. 1999;104:424–425
  16. Pitini V, Arrigo C, Aloi G, Mesiti M, Righi M, Calapso P, et al. Effect of treatment with amifostine in pts. with myelodysplastic syndromes on clinical outcome and apoptosis in bone marrow. Proc Am Soc Clin Oncol. 2001;[abstract 1210]
  17. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  18. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposal for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199
  19. Haase D, Feurig-Buske M, Könemann S, Fonatsch C, Troff C, Verbeek W, et al. Evidence of malignant transformation in acute myeloid leukemia at the level of early hematopoetic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood. 1995;86:2906–2912
  20. Mitelman F. ISCN: Guidelines for cancer cytogenetics. Supplement to an International System for Human Cytogenetic Nomenclature. Basel: S. Karger; 1995.
  21. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425
  22. National Cancer Institute (NCI): Common toxicity criteria. Bethesda, MD, USA: Division of Cancer Treatment, National Cancer Institute; 1988.
  23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  24. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized trials requiring prolonged observation of each patient. II. Analysis example. Br J Cancer. 1977;35:1–39
  25. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Raymond T, et al. Stimulation of hematopoiesis by amifostine in pts. with myelodysplastic syndrome. Blood. 1997;90:3364–3369
  26. Bowen DT, Denzlinger C, Brugger W, Culligan D, Gelly K, Adlakha S, et al. Poor response rate to a continuous schedule of amifostine therapy for ‘low/intermediate risk’ myelodysplastic pts. Br J Haematol. 1998;103:785–787
  27. Brasfield FM, Heaton R, Glinsmann-Gibson B, Obregon Y, Talley M, Taetle R, et al. phase I/II trial of subcutaneous amifostine in pts. with myelodysplastic syndrome (MDS) (meeting abstract). Proc Am Soc Clin Oncol. 1998;17:[abstract 13]
  28. De Castro CM, Gockermann JP, Moore JO, Hartung C, Misuraca J. Treatment of myelodysplastic syndrome (MDS) with amifostine. Leuk Res. 1999;23:77;[abstract 204]
  29. Denzlinger C, Benz D, Gelly K, Hepburn M, Brugger W, Kanz L, et al. Amifostine for myelodysplastic syndromes: poor response rate to a continuous schedule. Ann Hematol. 1998;(Suppl. 2):56;[abstract 220]
  30. Galanopoulos A, Kritikou-Griva E, Gligori J, Michalis E, Grigoraki V, Marinakis T, et al. Treatment of pts. with myelodysplastic syndrome with amifostine. Leuk Res. 2001;25:665–671
  31. Grossi A, Fabbri A, Santini V, Leoni F, Nozzoli C, Longo G, et al. Amifostine in the treatment of low-risk myelodysplastic syndromes. Haematologica. 2000;85:367–371
  32. Hoffmann W-K, Seipelt G, Ottmann OG, Kalina U, Koschmieder S, Brücher J, et al. Effect of treatment with amifostine used as a single agent in pts. with refractory anemia on clinical outcome and serum tumor necrosis factor α levels. Ann Hematol. 2000;79:255–258
  33. Jarchum G, Ryser R, Bove V, Garcia J, Minoldo D, Heller V, et al. Treatment of myelodysplastic syndrome (MDS) with amifostine (AMF). Blood. 1997;90(Suppl. 288b):[abstract 4041]
  34. Kempin S, Sirott M, Cecchi G, Irwin D, Gee T, Stepan D, et al. Phase II study of amifostine for the treatment of the myelodysplastic syndrome (MDS) (meeting abstract). Proc Am Soc Clin Oncol. 1998;18:[abstract 108]
  35. Ribeiro E, Lima CS, Metze K, Souca C, Lorand-Metze I. Changes in hematopoietic precursors after treatment of low-risk myelodysplasia with amifostine. In Vivo. 2003;17:181–184
  36. Tefferi A, Elliott M, Steensma DP, Hook CC, Dispenzieria A, Hanson CA, et al. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res. 2001;25:183–185
  37. Terebelo H, Marsico D, Shurafa M, Karanes C. A Phase II trial of amifostine in pts. with advanced myelodysplastic syndromes (meeting abstract). ASCO. 1999;[abstract 82]
  38. Viniou N, Terpos E, Galanopoulos A, Kritikou-Griva E, Akel S, Michalis E, et al. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response. Ann Hematol. 2002;81:182–186
  39. Petti MC, Latagliata R, Breccia M, Alimena G, Spadea A, D’Andrea M, et al. Spontaneous remission in adult pts. with de novo myelodysplastic syndrome: a possible event. Haematologica. 2001;12:1277–1280
  40. Yilmaz A, Kaufmann CC, Binder C, Wörmann B, Haase D. Effects of amifostine in a patient with advanced-stage myelodysplastic syndrome. Ann Hematol. 2001;80:53–57

PII: S0145-2126(09)00154-4

doi: 10.1016/j.leukres.2009.03.027

Leukemia Research
Volume 33, Issue 9 , Pages 1183-1188 , September 2009

Article Tools

* Image Usage & Resolution